PFE Jun 2024 27.000 call
| Previous close | 1.1600 |
| Open | 1.6600 |
| Bid | 1.6800 |
| Ask | 2.4500 |
| Strike | 27.00 |
| Expiry date | 2024-06-14 |
| Day's range | 1.6100 - 1.7600 |
| Contract range | N/A |
| Volume | |
| Open interest | 685 |
Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
Business WirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NEW YORK, June 01, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891] p=0
- Insider Monkey
The Most Profitable Biotechnology Company in the World
In this article, we will be taking a look at the most profitable biotechnology company in the world. If you want to learn about more, head straight to the 15 Most Profitable Biotechnology Companies in the World. Global Biotechnology Market Forecast: Strong Growth Driven by Healthcare and Food & Agriculture Innovations The global biotechnology market was valued […]
